GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM

Launched by DUKE UNIVERSITY · Jan 20, 2023

Keywords

ClinConnect Summary

The GRETeL trial is studying patients with a type of brain cancer called glioblastoma (GBM) to understand how their tumors change over time. Researchers want to find out if certain pieces of DNA found in the blood, known as circulating tumor DNA (ctDNA) or cell-free DNA (cfDNA), can help predict how the disease will behave, including if it will come back and how long patients might live after treatment. This study is important because it could help doctors tailor treatments based on a patient's unique tumor characteristics.

To be eligible for this trial, participants must be at least 18 years old, have recently been diagnosed with a specific type of malignant glioma, and have had surgery to remove their tumor. They also need to be planning to receive standard radiation therapy combined with a medication called temozolomide. Participants will undergo regular brain scans and provide some leftover tissue from their surgery for the study. It's important to note that people with certain prior cancers currently being treated are not eligible for this trial. By joining this study, participants may contribute to important research that could improve future treatments for GBM.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Patients newly diagnosed with malignant glioma, IDH wildtype who have undergone surgical resection for their tumor and who are planned for standard of care radiation therapy with concurrent temozolomide (i.e., at least 59 Gy in 30 fractions over 6 weeks)
• • Patients must have leftover tissue available from the surgical resection of their tumor available to request for this research.
• • Able to undergo MRI of brain with and without contrast
• • Signed informed consent approved by the Institutional Review Board (IRB)
• Exclusion Criteria:
• • Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin